These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 36600187)

  • 1. Biomarkers of haemodynamic severity of systemic sclerosis-associated pulmonary arterial hypertension by serum proteome analysis.
    Sanges S; Rice L; Tu L; Valenzi E; Cracowski JL; Montani D; Mantero JC; Ternynck C; Marot G; Bujor AM; Hachulla E; Launay D; Humbert M; Guignabert C; Lafyatis R
    Ann Rheum Dis; 2023 Mar; 82(3):365-373. PubMed ID: 36600187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-32 in systemic sclerosis, a potential new biomarker for pulmonary arterial hypertension.
    Di Benedetto P; Guggino G; Manzi G; Ruscitti P; Berardicurti O; Panzera N; Grazia N; Badagliacca R; Riccieri V; Vizza CD; Radchenko G; Liakouli V; Ciccia F; Cipriani P; Giacomelli R
    Arthritis Res Ther; 2020 Jun; 22(1):127. PubMed ID: 32487240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Haemodynamic phenotypes and survival in patients with systemic sclerosis: the impact of the new definition of pulmonary arterial hypertension.
    Xanthouli P; Jordan S; Milde N; Marra A; Blank N; Egenlauf B; Gorenflo M; Harutyunova S; Lorenz HM; Nagel C; Theobald V; Lichtblau M; Berlier C; Ulrich S; Grünig E; Benjamin N; Distler O
    Ann Rheum Dis; 2020 Mar; 79(3):370-378. PubMed ID: 31818805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-terminal pro-brain natriuretic peptide in a novel screening algorithm for pulmonary arterial hypertension in systemic sclerosis: a case-control study.
    Thakkar V; Stevens WM; Prior D; Moore OA; Byron J; Liew D; Patterson K; Hissaria P; Roddy J; Zochling J; Sahhar J; Nash P; Tymms K; Celermajer D; Gabbay E; Youssef P; Proudman SM; Nikpour M
    Arthritis Res Ther; 2012 Jun; 14(3):R143. PubMed ID: 22691291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Idiopathic and Systemic Sclerosis-Associated Pulmonary Arterial Hypertension: A Comparison of Demographic, Hemodynamic, and MRI Characteristics and Outcomes.
    Ramjug S; Hussain N; Hurdman J; Billings C; Charalampopoulos A; Elliot CA; Kiely DG; Sabroe I; Rajaram S; Swift AJ; Condliffe R
    Chest; 2017 Jul; 152(1):92-102. PubMed ID: 28223154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hemodynamic Response to Treatment and Outcomes in Pulmonary Hypertension Associated With Interstitial Lung Disease Versus Pulmonary Arterial Hypertension in Systemic Sclerosis: Data From a Study Identifying Prognostic Factors in Pulmonary Hypertension Associated With Interstitial Lung Disease.
    Chauvelot L; Gamondes D; Berthiller J; Nieves A; Renard S; Catella-Chatron J; Ahmad K; Bertoletti L; Camara B; Gomez E; Launay D; Montani D; Mornex JF; Prévot G; Sanchez O; Schott AM; Subtil F; Traclet J; Turquier S; Zeghmar S; Habib G; Reynaud-Gaubert M; Humbert M; Cottin V
    Arthritis Rheumatol; 2021 Feb; 73(2):295-304. PubMed ID: 32892515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical phenotypes, hemodynamic characteristics and prognosis of Chinese patients with systemic sclerosis-associated precapillary pulmonary hypertension: a retrospective study.
    Yuan YP; Yuan P; Su YL; Jiang R; Zhang R; He J; Qiu HL; Luo CJ; Liu JM; Gong SG; Wang L; Zhao QH
    Clin Rheumatol; 2022 Jun; 41(6):1675-1686. PubMed ID: 35099674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pulmonary hypertension in systemic sclerosis: diagnosis by systematic screening and prognosis after three years follow-up.
    Vilela VS; Dias MM; Salgado ÂA; da Silva BRA; Lopes AJ; Bessa EJC; Bruno LP; da Costa CH; Levy RA; Rufino R
    BMC Pulm Med; 2021 Jul; 21(1):251. PubMed ID: 34325685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening for pulmonary arterial hypertension in patients with systemic sclerosis in the era of new pulmonary arterial hypertension definitions.
    Erdogan M; Kilickiran Avci B; Ebren C; Ersoy Y; Ongen Z; Ongen G; Hamuryudan V; Hatemi G
    Clin Exp Rheumatol; 2024 Aug; 42(8):1590-1597. PubMed ID: 38489342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vascular receptor autoantibodies in pulmonary arterial hypertension associated with systemic sclerosis.
    Becker MO; Kill A; Kutsche M; Guenther J; Rose A; Tabeling C; Witzenrath M; Kühl AA; Heidecke H; Ghofrani HA; Tiede H; Schermuly RT; Nickel N; Hoeper MM; Lukitsch I; Gollasch M; Kuebler WM; Bock S; Burmester GR; Dragun D; Riemekasten G
    Am J Respir Crit Care Med; 2014 Oct; 190(7):808-17. PubMed ID: 25181620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aberrant long-chain fatty acid metabolism associated with evolving systemic sclerosis-associated pulmonary arterial hypertension.
    Coursen JC; Tuhy T; Naranjo M; Woods A; Hummers LK; Shah AA; Suresh K; Visovatti SH; Mathai SC; Hassoun PM; Damico RL; Simpson CE
    Am J Physiol Lung Cell Mol Physiol; 2024 Jul; 327(1):L54-L64. PubMed ID: 38651694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decreased biventricular longitudinal strain in patients with systemic sclerosis is mainly caused by pulmonary hypertension and not by systemic sclerosis per se.
    Lindholm A; Hesselstrand R; Rådegran G; Arheden H; Ostenfeld E
    Clin Physiol Funct Imaging; 2019 May; 39(3):215-225. PubMed ID: 30597705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum biomarker for diagnostic evaluation of pulmonary arterial hypertension in systemic sclerosis.
    Rice LM; Mantero JC; Stratton EA; Warburton R; Roberts K; Hill N; Simms RW; Domsic R; Farber HW; Layfatis R
    Arthritis Res Ther; 2018 Aug; 20(1):185. PubMed ID: 30115106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Whole blood viscosity in systemic sclerosis: a potential biomarker of pulmonary hypertension?
    Senturk B; Akdeniz B; Yilmaz MB; Ozcan Kahraman B; Acar B; Uslu S; Birlik M
    Clin Rheumatol; 2020 Jan; 39(1):49-56. PubMed ID: 31129792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kynurenine pathway metabolism evolves with development of preclinical and scleroderma-associated pulmonary arterial hypertension.
    Simpson CE; Ambade AS; Harlan R; Roux A; Aja S; Graham D; Shah AA; Hummers LK; Hemnes AR; Leopold JA; Horn EM; Berman-Rosenzweig ES; Grunig G; Aldred MA; Barnard J; Comhair SAA; Tang WHW; Griffiths M; Rischard F; Frantz RP; Erzurum SC; Beck GJ; Hill NS; Mathai SC; Hassoun PM; Damico RL;
    Am J Physiol Lung Cell Mol Physiol; 2023 Nov; 325(5):L617-L627. PubMed ID: 37786941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relation of novel echocardiographic measures to invasive hemodynamic assessment in scleroderma-associated pulmonary arterial hypertension.
    Gopal DM; Doldt B; Finch K; Simms RW; Farber HW; Gokce N
    Arthritis Care Res (Hoboken); 2014 Sep; 66(9):1386-94. PubMed ID: 24515598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study.
    Coghlan JG; Denton CP; Grünig E; Bonderman D; Distler O; Khanna D; Müller-Ladner U; Pope JE; Vonk MC; Doelberg M; Chadha-Boreham H; Heinzl H; Rosenberg DM; McLaughlin VV; Seibold JR;
    Ann Rheum Dis; 2014 Jul; 73(7):1340-9. PubMed ID: 23687283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble markers of B cell activation suggest a role of B cells in the pathogenesis of systemic sclerosis-associated pulmonary arterial hypertension.
    Sanges S; Guerrier T; Duhamel A; Guilbert L; Hauspie C; Largy A; Balden M; Podevin C; Lefèvre G; Jendoubi M; Speca S; Hachulla É; Sobanski V; Dubucquoi S; Launay D
    Front Immunol; 2022; 13():954007. PubMed ID: 35967377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vascular endothelial injury assessed with functional techniques in systemic sclerosis patients with pulmonary arterial hypertension versus systemic sclerosis patients without pulmonary arterial hypertension: a systematic review and meta-analysis.
    Theodorakopoulou MP; Minopoulou I; Sarafidis P; Kamperidis V; Papadopoulos C; Dimitroulas T; Boutou AK
    Rheumatol Int; 2021 Jun; 41(6):1045-1053. PubMed ID: 33830321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Target organ expression and biomarker characterization of chemokine CCL21 in systemic sclerosis associated pulmonary arterial hypertension.
    Didriksen H; Molberg Ø; Mehta A; Jordan S; Palchevskiy V; Fretheim H; Gude E; Ueland T; Brunborg C; Garen T; Midtvedt Ø; Andreassen AK; Lund-Johansen F; Distler O; Belperio J; Hoffmann-Vold AM
    Front Immunol; 2022; 13():991743. PubMed ID: 36211384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.